This document provides guidance on establishment licensing, product quality and lot release to bring a COVID-19 vaccine to market in Canada.

The 2019 coronavirus (COVID-19) pandemic revealed the urgent need for the acceleration of vaccine development worldwide. Rapid vaccine development poses numerous risks for each category of vaccine technology. By using the Risklick artificial intelligence (AI), we estimated the risks associated with all types of COVID-19 vaccine during the early phase of vaccine development. We then performed a postmortem analysis of the probability and the impact matrix calculations by comparing the 2020 prognosis to the contemporary situation. We used the Risklick AI to evaluate the risks and their incidence associated with vaccine development in the early stage of the COVID-19 pandemic. Our analysis revealed the diversity of risks among vaccine technologies currently used by pharmaceutical companies providing vaccines. This analysis highlighted the current and future potential pitfalls connected to vaccine production during the COVID-19 pandemic. Hence, the Risklick AI appears as an essential tool in vaccine development for the treatment of COVID-19 in order to formally anticipate the risks, and increases the overall performance from the production to the distribution of the vaccines. The Risklick AI could, therefore, be extended to other fields of research and development and represent a novel opportunity in the calculation of production-associated risks.

COVID-19 Reopening Data from Associated Press and Kantar Media

Access regularly updated data from The Associated Press and Kantar Media containing information on events at the global, national and state levels as economies reopen following the coronavirus pandemic via AP Planner.

AP Planner is a paid service from The Associated Press & Kantar Media.

The four data files below feature the following event types:

• Environmental, Social and Governance (ESG): Events related the factors that measure the sustainability and societal impact of an investment in a company or business.
• Healthcare, Pharmaceuticals and Bio Tech: Health care providers and services, health care equipment and supplies, and health care technology companies. Drug and vaccine production, as well as biological substances for the purposes of drug discovery and diagnostic development.
• Politics: U.S. political news and events.
• Diversity and Discrimination: News and events related to race, religion, gender, sexuality, disability and age.

All data is compiled by a dedicated staff with over 15 years of forward planning research experience, employing data verification and processes designed to provide reliable and up-to-date information.

The data can be used to help:

• Provide signals to investors on how to act and at what speed based on the types of events returning across industries.
• Analyze risk associated with companies based on when they're reopening.
• Retain your own customer base based on reopening dates for vendors and competitors.
• Track COVID regulations to prepare inventory and guest policies.

The following data files are samples - if you are interested in licensing the full, regularly updated database, please contact Opal Barclay (obarclay@ap.org) at The Associated Press or Click on Request Access Button above.

​

***

FAQs

Why does AP and Kantar compile this data?_ The data is sourced from AP Planner, a product offered by The Associated Press and Kantar Media. AP Planner is a searchable database of future events that is updated daily and intended for research, not publication.

What information does AP Planner contain?_ AP Planner is global in scope and contains more than 100,000 U.S. and international events from the world of news, current affairs, politics, business, lifestyle and more - all searchable up to 12 months ahead.

Where does the information come from?_ AP Planner aggregates listings from tens of thousands of organizations worldwide. Our research staff monitors over 350,000 websites and uses a verity of secondary sources including press releases, corporate announcements and other outlets to ensure accuracy.

How can I be confident of the data's quality and accuracy?_ We have a dedicated research staff with over 15 years of forward planning research experience. They employ data verification and updating processes designed to provide our customers with completely reliable and up-to-date information.

Can I export data into other applications?_ Yes, AP Planner data can be exported as an Excel file or an Outlook calendar file. The data is also accessible via API.

Who can I contact to learn more about AP Planner?_ Opal Barclay, obarclay@ap.org.

This feature layer is part of SDGs Today. Please see sdgstoday.orgThe Launch and Scale Speedometer, led by the Duke Global Health Innovation Center, has tracked COVID-19 vaccine purchase agreements between November 2020 and June 2022. This dataset provides the most recent data on vaccine purchases and negotiations by individual countries and unilateral partnerships from 16 companies. Unilateral partnerships include the African Union, European Union, Latin America excluding Brazil, and COVAX, the global initiative aimed to produce, procure, and distribute vaccines to member countries.So far, 14.9 billion doses have been reserved. Confirmed doses are deals that have been signed and finalized. Potential doses include both deals that are under negotiation (not yet final) and also options for additional doses as part of existing confirmed deals.For more information, contact info@launchandscalefaster.org

Owing to the success of linear mRNA coronavirus disease 2019 (COVID-19) vaccines, biopharmaceutical companies and research teams worldwide have attempted to develop more stable circular RNA (circRNA) vaccines and have achieved some preliminary results. This review aims to summarize key findings and important progress made in circRNA research, the in vivo metabolism and biological functions of circRNAs, and research progress and production process of circRNA vaccines. Further, considerations regarding the quality control of circRNA vaccines are highlighted herein, and the main challenges and problem-solving strategies in circRNA vaccine development and quality control are outlined to provide a reference for circRNA vaccine-related research.

Abstract: We examine the implications of the very low competitiveness of the Brazilian vaccine RD&I system, which precludes the development of all the important vaccines required by the National Immunization Program (NIP), severely impacting the healthcare of the population. In a country dramatically affected by COVID-19 pandemic and by an exponential increase in emerging and neglected diseases, particularly the poor, these RD&I constraints for vaccines become crucial governance issues. Such constraints are aggravated by a global scenario of limited commercial interest from multinational companies in vaccines for neglected and emerging diseases, which are falling into a “valley of death,” with only two vaccines produced in a pipeline of 240 vaccines. We stress that these constraints in the global pipeline are a window of opportunity for vaccine manufacturers in Brazil and other developing countries in the current paradigm transition towards Vaccinology 4.0. We conclude with recommendations for a new governance strategy supporting Brazilian public vaccine manufacturers in international collaborations for a sustainable national vaccine development and production plan by 2030.

💉 COVID-19 Vaccine Adverse Events (2020-2025): VAERS Real-World Surveillance Data This dataset offers a critical, large-scale look into the real-world safety surveillance of COVID-19 vaccines, sourced from the Vaccine Adverse Event Reporting System (VAERS). Maintained by the CDC and FDA, this collection spans the unprecedented period of mass vaccination from 2020 through 2025, providing an invaluable resource for pharmacovigilance, public health research, and regulatory decision-making.

Key Features & Challenge The dataset is a rich blend of structured and unstructured information detailing reported Adverse Drug Events (ADEs), which range from mild local reactions to severe, life-threatening complications.

Structured Data: Includes standardized symptom codes, offering a direct, quantitative view of reported reactions.

Free-Text Notes: Contains verbose, real-world symptom descriptions provided by reporters. This text is a "treasure trove" of granular context, including details on duration, intensity, and location of symptoms.

The Challenge: The structured entries are limited in scope. The free-text notes, while rich, are inherently noisy and lack standardized metadata such as clinical severity scores or age-specific pattern normalization.

Value to Data Scientists This dataset presents a significant Natural Language Processing (NLP) and Machine Learning (ML) challenge:

Extracting Context: Develop models to effectively extract critical clinical context (e.g., "headache lasting three days, severe") from the raw, non-standardized free-text notes.

Standardizing Severity: Create predictive models to assign standardized severity and age-specific risk patterns to ADEs.

Informed Decision Making: The ultimate goal is to generate actionable, timely insights for regulators, healthcare providers, and pharmaceutical companies, improving both vaccine safety monitoring and public trust.

Dive into this dataset to apply your skills in advanced data cleaning, feature engineering, and state-of-the-art NLP to solve a crucial, high-impact public health challenge.

Accounts-Payable Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells in vitro diagnostic reagents and instruments, and vaccines in China and internationally. It operates through Diagnostics Division and Vaccine Division segments. The company offers chemiluminescence detection, biochemical, hepatitis B core antibody detection, and HIV reagents; rapid urine tests for hepatitis E antigen; chronic disease management, hepatitis E screening and prevention, women's full life-cycle health management, smart laboratories, medical laboratory quality and competence accreditation, lean management consulting, blood safety testing, and internal quality control solutions; enzyme-linked immunosorbent assay, colloidal gold, nucleic acid, clinical test quality control products, and raw materials; and nucleic acid testing devices. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccines. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests; biochemical assays comprising helicobacter pylori antibodies, gastrin 17, and soluble transferrin receptors; and support services, such as after-sales and training center services. Additionally, the company engages in technology business incubation and development activities. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a subsidiary of Yangshengtang Co., Ltd.

Stock Price Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells vitro diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccine. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests, as well as support services. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates as a subsidiary of Yangshengtang Co., Ltd.

To facilitate effective targeted COVID-19 vaccination strategies, it is important to understand reasons for vaccine hesitancy where uptake is low. Artificial intelligence (AI) techniques offer an opportunity for real-time analysis of public attitudes, sentiments, and key discussion topics from sources of soft-intelligence, including social media data. In this work, we explore the value of soft-intelligence, leveraged using AI, as an evidence source to support public health research. As a case study, we deployed a natural language processing (NLP) platform to rapidly identify and analyse key barriers to vaccine uptake from a collection of geo-located tweets from London, UK. We developed a search strategy to capture COVID-19 vaccine related tweets, identifying 91,473 tweets between 30 November 2020 and 15 August 2021. The platform's algorithm clustered tweets according to their topic and sentiment, from which we extracted 913 tweets from the top 12 negative sentiment topic clusters. These tweets were extracted for further qualitative analysis. We identified safety concerns; mistrust of government and pharmaceutical companies; and accessibility issues as key barriers limiting vaccine uptake. Our analysis also revealed widespread sharing of vaccine misinformation amongst Twitter users. This study further demonstrates that there is promising utility for using off-the-shelf NLP tools to leverage insights from social media data to support public health research. Future work to examine where this type of work might be integrated as part of a mixed-methods research approach to support local and national decision making is suggested.

Income-Before-Tax Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells vitro diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccine. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests, as well as support services. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates as a subsidiary of Yangshengtang Co., Ltd.

Dividends-Paid Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells vitro diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccine. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests, as well as support services. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates as a subsidiary of Yangshengtang Co., Ltd.

Other-Cashflows-From-Investing-Activities Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells in vitro diagnostic reagents and instruments, and vaccines in China and internationally. It operates through Diagnostics Division and Vaccine Division segments. The company offers chemiluminescence detection, biochemical, hepatitis B core antibody detection, and HIV reagents; rapid urine tests for hepatitis E antigen; chronic disease management, hepatitis E screening and prevention, women's full life-cycle health management, smart laboratories, medical laboratory quality and competence accreditation, lean management consulting, blood safety testing, and internal quality control solutions; enzyme-linked immunosorbent assay, colloidal gold, nucleic acid, clinical test quality control products, and raw materials; and nucleic acid testing devices. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccines. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests; biochemical assays comprising helicobacter pylori antibodies, gastrin 17, and soluble transferrin receptors; and support services, such as after-sales and training center services. Additionally, the company engages in technology business incubation and development activities. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a subsidiary of Yangshengtang Co., Ltd.

Free-Cash-Flow-To-The-Firm Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells vitro diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccine. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests, as well as support services. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates as a subsidiary of Yangshengtang Co., Ltd.